Stock News & Analysis

One Wall Street analyst is extremely bullish on NuScale Power stock.

Why did Twilio stock soar 20% today? A bullish analyst says the turnaround is complete.

Recent results reveal a stark contrast in revenue trends and profitability margins for these electric vehicle makers.

Best Buy offers one of the highest yields on the S&P 500.

One dominates globally with billions in free cash flow; the other accelerates U.S. growth with a lean drive-thru model. Their financial paths diverge sharply.

Want to celebrate the Dow's 130th birthday? Consider the Invesco Dow Jones Industrial Average Dividend ETF.

The IPO market is heating up, and both stocks have promise, but one looks like the better investment right now.

The company's new CEO will take over in September and won't have to worry about the founder criticizing their every move, at least for a while.

Analysts appear to be bracing for bad news.

Micron was valued at around $100 billion a year ago.

The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S. exposure, while the other adds global reach in a sector shaped by drug pricing, patent cycles, regulation, and medical innovation.

Big enterprise software companies saw a relief rally after Nvidia's Jensen Huang gave positive remarks on the future of software, and Salesforce made a splashy announcement in France.

Nvidia's new Vera platform unlocks a $200 billion market opportunity for the business.

Some shareholders are selling shares of the nuclear energy giant. You should probably buy instead. Here's why.

SpaceX just filed its S-1 ahead of what could be the largest IPO in history.

CORO offers active non-U.S. equity exposure through BlackRock’s country-rotation process. The fund’s case rests on whether that flexibility can improve international allocation beyond a passive benchmark.

This could save you thousands of dollars in taxes this year.

The company recently posted a stellar quarter with its growth rate rising to 88%.

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

AI might really change everything. That doesn't mean every AI stock is a buy right now.